{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000967","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.128454+00:00","generated_at":"2026-06-05T16:15:14.789125+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit","bullets":["ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).","2024 guidance: ORLADEYO revenue $380-$400M; expects operating profit in 2024, positive EPS and cash flow in 2H 2025.","GAAP net loss Q4 $61.7M ($0.31), FY2023 $226.5M ($1.18); non-GAAP net loss Q4 $56.4M ($0.28).","R&D expenses fell to $70.1M Q4 (-4% yoy); SG&A rose to $64.4M Q4 (+28% yoy) on commercial expansion.","Cash $390.8M at Dec 31, 2023; net cash use $8.6M in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000967","json":"https://secwatch.observer/filing/0001171843-24-000967.json","markdown":"https://secwatch.observer/filing/0001171843-24-000967.md","text":"https://secwatch.observer/filing/0001171843-24-000967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/0001171843-24-000967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/f8k_022624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:15:14.789125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"139b67ae6e86fdfd13a1e2fc79130d94d011026b","claim":"BIOCRYST PHARMACEUTICALS INC updated its the fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 26, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/0001171843-24-000967-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}